

燃 DISCLAIMER

This document ("Document") has been prepared by Eximius Capital Ventures Private Limited, the investment manager ("Investment Manager") of Eximius Fund ("Fund") in respect of a limited review period, solely for informational purposes. The information, data, analyses and opinions ("Information") contained in the Document are provided on an "as is" basis and may be subject to change, at the sole discretion of the Investment Manager.

This Document should not be regarded as an official opinion of any kind or a recommendation or definitive statement on the investment strategy or investments or returns of the Fund. The information contained in this Document: (1) is obtained from or based on sources believed to be reliable, (2) is not warranted to be complete, accurate, exhaustive or timely, and (3) should not be construed as investment advice or as any research report. Except where otherwise indicated herein, the Information provided in this Document is based on matters as they exist as of the date of this Document and not as of any future date. The Fund or the Investment Manager does not have any obligation to and does not provide any undertaking to update or otherwise revise any Information in the Document, reflecting circumstances arising after the date of this Document.

This Document and the contents hereof are strictly confidential in nature and are intended for use by the recipient only. By accepting delivery of this Document, the recipient agrees to maintain confidentiality of the same. The ownership of any intellectual property (including any copyright) arising from or in respect of any material, text, article, information or a compilation thereof referenced in this Document, that is created and/or owned by the Investment Manager, Fund and/or third parties, shall continue to remain and vest in such persons, and no ownership or right to such intellectual property shall be deemed to have been granted, transferred, licensed, sold, disposed of or otherwise vested in the recipient of this Document (except as provided hereunder). The Information shall, accordingly, not be circulated, copied, reproduced, redistributed, retransmitted or disclosed, in whole or in part, or any form or manner, without the prior express written consent of the Investment Manager. If this Document has been received in error, it must be returned immediately to the Investment Manager.

The Investment Manager or the Fund does not make any warranty as to the contents of the Document and/or the Information's accuracy or completeness and the Investment Manager or the Fund does not assume any responsibility for any mistakes, inaccuracy or incompleteness of the same. Recipients are advised to seek independent advice at their discretion, as to any applicable legal, financial, tax or other considerations, which might be relevant or required by them, in connection with this Document.

Neither the Fund nor the Investment Manager is to be liable for any loss or damage whatsoever in connection with this Document or the Information contained herein. Projected market and financial information, analyses, and conclusions contained in the Document should not be construed as definitive forecasts or guarantees of future performance or results. Any forward-looking statements (including, without limitation, projections of future earnings or value) contained herein, which can generally be identified by the use of forward-looking terminology such as "may," "will," "should," "expect," "anticipate," "project," "estimate," "intend," "continue," "target" or "believe" or the negatives thereof or other variations thereon or comparable terminology, are subject to known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from those contemplated herein.

燃 ABOUT US

<u>Eximius Ventures</u> is a dedicated **pre-seed fund** offering smart capital with deep knowledge. As a **sector-differentiated** fund, we invest around \$500k in the pre-product/early traction stage, employing a **thesis-driven approach** across **FinTech, Consumer Tech & Enterprise AI, with an AI-first approach across all sectors.**

We strive to support exceptional operators in building groundbreaking solutions for India. A substantial portion of our fund is reserved for follow-on rounds, showcasing our long-term support. Recognising the need for agility in the dynamic startup ecosystem, we've established an efficient and transparent decision-making process, ensuring founders receive capital without unnecessary delays.

Beyond capital infusion, our Eximius Edge Platform extends comprehensive support to founders.









We aim to identify and back exceptional founders leveraging the strong demographic dividend of India to build from India to the world, helping them with a unique value-add.

Our Value-adds



Founder Centric Approach




Speed of Decision and Execution



Sector-specific Knowledge and Expertise



Functional Support for Business



Strong Brand Presence, But With Value-add



LinkedIn Followers



Hours of content



Likes and Impressions





Decover

然 TABLE OF CONTENTS


INDUSTRY OVERVIEW	5 - 6
INDUSTRY TRENDS	7 - 8
WHY THE TIME TO SOLVE THIS IS NOW	9
THE BOTTLENECKS TO SOLVE	10
VC FUNDED COMPANIES (DOMESTIC)	11
NIVAAN DEEPDIVE	12
SWORD: LEADING GLOBAL PLAYER IN THE SPACE	13
EMERGING WHITESPACES	14
CONCLUSION	15




INDUSTRY OVERVIEW

Growth in the pain management market has been engendered by rising health awareness in the post-Covid era. With the broader preventative healthcare sector expected to reach \$500Bn by 2030, patients are more willing than ever to seek redressal for their grievances. To meet this growing demand, around five new pain relief brands have been launched each week on average since the onset of the pandemic.

INDUSTRY SIZE (\$BN)



MARKET SPLIT




CLASSIFICATION


- **Restorative Care** Recovery from a critical condition, typically required after complex surgeries/procedures such as brain injury, spinal injury, knee replacement, etc.
- Pain Relief Relief from acute & chronic pains in physiotherapy-based care in conditions such as arthritis, back pain, etc.
- **Geriatric Care** Medical care and comorbidities focused on elderly needs for ailments like dementia, Parkinson's, etc.

HIGHLIGHTS

- Top 10 cities account for ~60% of the spend on restorative care, given the higher concentration of tertiary care hospitals in these cities (where majority of complex surgeries & procedures are performed).
- Geriatric care and pain relief spends are more evenly distributed, yet top 10 cities have a sizeable contribution.

浏 INDUSTRY OVERVIEW (CONT.)







KEY TAKEAWAYS:

- Over 200 million people in India suffer from chronic pain, with 19.3% of adult Indians affected and an average duration of 4.2 years per patient.
- Surgical and implant-based interventions dominate the pain relief market, accounting for over 69% of sub-segment share.
- Top 10 cities account for ~30% of pain relief spend, with the majority of value distributed across Tier 2/3 cities, indicating a massive opportunity for regional expansion.
- Restorative care is highly centralized, with ~60% of spend concentrated in top-tier metros due to the presence of tertiary care hospitals.
- The market is growing fast, driven by increasing awareness, rising demand for preventative healthcare, and long LTV potential in chronic care pathways.



INDUSTRY TRENDS: WHAT DO THE UNIT ECONOMICS LOOK LIKE?





KEY TAKEAWAYS:

- Choice of treatment is highly context-dependent: Patients opt for restorative care when facing critical or post-surgical recovery needs (e.g., spinal/knee/brain injuries) procedures that are intensive, hospital-led, and offer high AOV. On the other hand, pain relief models cater to chronic conditions like arthritis or back pain, with more flexible, OPD/physiotherapy-led formats and lower CAC.
- Geriatric care providers often treat chronic comorbidities (e.g., Parkinson's, dementia), which require long-term adherence. However, lack of awareness and poor funnel design often result in <5% of patients reaching post-rehab stages causing LTVs to remain depressed.
- While restorative care enjoys the highest margins and LTVs, it's also the most specialized and capital-intensive. Pain relief, meanwhile, offers strong margins due to low COGS and is best suited for full-stack players with sticky recovery modules and upsell adjacencies (therapy, nutrition, ergonomic tools).
- Trust, quality, and omnichannel discovery are key drivers. Given how fragmented supply is, discovery is often word-of-mouth.



INDUSTRY TRENDS: PROBLEM STATEMENTS



While 200 million people in India suffer from chronic pain, 42% end up visiting only a general practitioner for relief. Even when people refer to specialist pain physicians (only 4.2%), there is a high reluctance (i.e. lack of trust) for drug-based therapies as 35% sufferers opt for treatments like massage and physical therapy.



Discovery is Broken



The biggest problem in non-drug and nonsurgery-based treatments is discovery. In addition to a dearth of qualified physiotherapists (0.59 for every 10,000), there are little consistencies in pedagogies which makes finding a perfect physiotherapist a nightmare for patients.



The funnel even after entering treatments faces incredibly low NPS and high attrition. >5% of the patient funnel adheres to the program and enters the post-rehab phase.

This needs to be resolved by increasing awareness about realistic outcomes and creating full-stack models that take end-to-end ownership of solutions.





Universal Problem Statement



With 200 million people as victims of chronic pain and over a quarter (25.2%) facing pain that limits body movement, the problem statement for pain management and alleviation is massive. As our population ages, the relevance and need for these solutions is only bound to increase further.



Increasing Awareness





While GTM and awareness have been the biggest problem statements in this space, the past few years have seen a massive change. 51% of Indians have started prioritizing health (from 11% pre-Covid), and 83% of people are now using pain or muscle-related medication for better quality of life.

Supply Ripe for Disruption



Due to the unorganized nature of the industry, the largest market share is held by large hospital chains and small isolated centres with positive WOM (Word of Mouth). Therefore, there is considerable market opportunity for models that bring supply together and enhance discovery.





* THE BOTTLENECKS TO SOLVE

Seamless GTM



Awareness and inertia amongst patients for finding a solution are the biggest problems with the space. This is especially true for service-led models as products like analgesics and surgeries can have a quicker TAT for relief. Therefore, CAC across models in this space tends to be quite high which is only exacerbated by low NPS and referral rates.

To mitigate the same, the best recourse would be to work in tandem with healthcare institutions to receive their patients and have their trust with those centres carry forward to the new treatment provider. Additionally, there is also a massive opportunity to create comprehensive platforms that list these centres and give patients the necessary information.

Low Stickiness



As difficult as it is to enroll a patient in the pain management funnel, retaining them is considerably higher which is why only <5% reach a post-rehab stage. Unrealistic expectations and low pain awareness are the biggest reasons for this issue which hinders the LTV per patient.

As discussed, having validation from the patient's primary treatment centre, and providing a comprehensive module of solutions will reduce patient churn considerably. Companies are specifically leveraging ancillary services like mental health check-ins or diet planning during treatment to reduce churn and make the patient feel supported.

<u>Integrated Product + Service</u>



>76% of the market is comprised of product-led solutions like medications, wearables, etc. Thus, the demand for services or models that empower services tends to be quite low. The product-led segments, on the other hand, have either monopolistic landscapes (especially surgeries and medications) or a higher barrier to attaining effective distribution.

The best model, therefore, needs to be holistic. Companies in this segment must create a stack of services and products that feels comprehensive and effective. While the former side is essential for long-term recourse and increasing the LTV, companies must also provide a dedicated arm to offer patients state-of-the-art products and treatments that can provide a more instantaneous impact when needed.

Omnichannel Necessity



Since 70% of the pain relief market resides outside the top 10 cities, founders need to optimise on distribution by having an omnichannel approach that optimises reach. While this expands the market considerably, this approach is also more operationally cumbersome for founders.

However, if founders are able to create a true omnichannel operation, they can benefit from the distribution boost of the online world, whilst also enjoying the legitimacy that an offline operation brings. With more experienced founders coming up, this is a trend that we see rapidly gathering steam.



次 VC FUNDED COMPANIES (DOMESTIC)







ABOUT	Nivaan is a pain management clinic that combines a multidisciplinary approach with a non-invasive philosophy to provide better outcomes to patients.	Osso provides expert orthopaedic care, advanced physiotherapy and complementary therapies for integrated healing and optimal outcomes.	Relievia acts as an end-to- end pain management concierge who uses their advanced pain centres, phygital physiotherapy, and a platform to track progress for driving outcomes.
FUNDING	\$5.43 Million raised in 2 rounds (W Health Ventures - through their venture studio & Endiya Partners)	\$402K across 2 rounds from Blume and a few angels.	Bootstrapped
REVENUE	\$1.5 Mn+ ARR	N/A	Projecting a revenue of \$300K in Y1
VALUATION	\$10.5M from seed (no. to be updated)	\$2.23M	N/A




NIVAAN DEEPDIVE (LEADING DOMESTIC PLAYER IN THE SPACE)



BUSINESS MODEL OVERVIEW

- Nivaan follows a phygital approach for pain management through its integrated solutions via its clinic in Delhi.
- The USP for Nivaan is its holistic approach to pain management through consultations with pain super-specialists, mindset counsellers, care managers, and nutritionists for driving better outcomes.
- Through this, they claim to be 9.3X more effective than any other pain treatment in the country.
- With their treatment, they provide pain alleviation for 1-1.5 yrs post which a customer would need to return.
- Nivaan was incubated by W Health through their venture studio, thus they built out their model.

FUNDING HISTORY



TREATMENT CATEGORIES

Knee Pain, Back Pain, Shoulder Pain, and Neck Pain.

WHAT IS MAKING NIVAAN WIN?

USD 1.5 MILLION+ ARR

30% MOM GROWTH

LTV OF INR 70-80K FOR CLIENTS WHO GO THROUGH ALL THE SESSIONS


They have a CAC of INR 2K.

Their GMV for new consult is 10-14K.

20,000+ sessions to date. PE interest exists in the space.



SWORD: LEADING GLOBAL PLAYER IN THE SPACE



ABOUT

Sword is an Al-powered platform to predict, prevent, and treat pain - combining world-class physical therapy expertise with an interactive, clinician-supervised digital experience.

With over 2 million AI sessions delivered and adoption across 10,000+ employers globally, Sword is saving clients millions while enabling superior pain recovery. The company also offers an upskilling platform for care providers and tools to detect high-risk patients early.

WHAT IS MAKING SWORD HEALTH WIN?

- Al-Led Personalisation at Scale
- Home-Based Recovery Model
- Massive Employer Distribution
- Built-in Upskilling Engine

FUNDING HISTORY

- Total Raised: **\$450 Mn**
- Rounds: 8
- Investors:



khosla ventures





REVENUE

Annual Recurring Revenue (ARR): \$200 Mn


VALUATION

Latest Valuation: **\$4 Bn**

MERGING WHITESPACES



One of the biggest challenges in this space is midtreatment churn from patients. To mitigate the same, it is important to create a comprehensive ecosystem of ancillary offerings like therapy, diet-planning, etc., for encouraging stickiness throughout the treatment. Platforms like Nivaan and Sword are not only personalising treatment, but also creating comprehensive programs that go beyond the treatment to support a patient through the process. This is where we see opportunity for new companies to marry cutting-edge tech with a full-stack approach to create real impact.



Discovery in the pain management space is primarily driven by word-of-mouth reviews in offline channels. Patients rarely have the facility of comprehensive discovery platforms to find experts near them and compare their offerings to find the right-fit. Therefore, the market needs solutions that list and provide comprehensive information for centres near a patient. Such a solution would open up the market for all players, and reduce the inertia that patients feel before starting a treatment.



TYPES OF COMPANIES VCS LOOK FOR:

- **Partnership-led GTM:** While patient awareness is increasing gradually, even the most aware of patients find discovering the right solution to be a hassle. To mitigate the same, players should look to partner with hospitals and other treatment centres to benefit from their patient-flow and increase conversion. This reduces their CACs and builds a degree of trust within the patients for the treatment.
- **High Long-term Retention:** Patient drop-off during treatment leads to severely diminished LTVs. Therefore, any treatment provider able to retain their patients for a prolonged period enjoys a competitive advantage over the competition. This can be achieved through the Nivaan model of creating an ecosystem of ancillary offerings like mental health check-ins, nutrition supports, etc. to boost the patient's morale.
- **High Organic Growth:** As discussed above, GTM is one of the most onerous hurdles in this space. Therefore, having a high organic acquisition rate implies extremely positive WOM and a high propensity to recommend amongst one's social circle. Moreover, it also acts as a testament to the effectiveness of the treatment and its ability to generate positive results. To achieve this, firms need to optimise their GTM funnels (both offline and online), in addition to providing effective treatment through the best solutions available. Satisfied customers are the best ambassadors for a company in this segment.
- Trust + Quality Led Platform: The business models in this industry are heavily dependent on strong WOM amongst users and retaining them in the funnel for a prolonged period. Therefore, VCs look for companies that are able to create a layer of trust with their customers through a meticulous emphasis on quality across the treatment lifecycle. This can only be ensured if the company is able to delivery high success rates and low churn across the funnel. A key strategy is to aggressively leverage tech to not just deliver key modules of the treatment virtually, but also to personalise the entire treatment journey for optimised results. This is how Sword has been able create high success rates for its treatment.

※ CONCLUSION



India's pain burden is massive - affecting over 200 million people - yet the market remains fragmented, under-penetrated, and trust-deficient. This makes it ripe for first-principles innovation.



Most patients drop off mid-treatment. Platforms that build full-stack, high-retention ecosystems (e.g., therapy, diet, ergonomics, etc.) will enjoy both clinical and commercial moats.



Discovery is broken. Patients rely heavily on referrals or local word-of-mouth. Platforms that offer verified expert listings, transparent pricing, and reviews can become the go-to layer for demand aggregation, i.e. Trust is paramount.



VCs are backing models with high organic growth, partnership-led GTM (e.g., with hospitals), and sticky cohorts. This favors startups with strong WOM and superior outcomes.



Key whitespace: glass-box models like Osso (orthopaedics) and global leaders like Sword (AI+PT) show that combining clinical care with tech-enabled delivery can unlock retention, outcomes, and category trust.



Investing in Founders From Ideation to Execution













eximiusvc.com/eximius-echo